Luis M. Ruilope

TL;DR: In this article , the authors evaluated the effects of finerenone on composite kidney and cardiovascular endpoints in varying stages of CKD (defined by estimated glomerular filtration rate [eGFR] and urine albumin-to-creatinine ratio [UACR]).

TL;DR: In this paper , finerenone, a selective, nonsteroidal mineralocorticoid receptor antagonist, showed cardiorenal benefits vs placebo in patients with chronic kidney disease and type 2 diabetes.

TL;DR: The demonstration that arterial hypertension is the number one risk factor in promoting death in developed as well as in developing countries fits well with the concept of JNC 7; however, the fact that prehypertension may correlate well with insulin resistance forces the consideration that the benefit of simply lowering BP may not be enough to correct the risk of elevated BP.

TL;DR: In this article , the hazard ratio (HR) of the key secondary composite kidney outcome in the insulin at baseline subgroup was incorrectly reported as 0.74 (95% CI 0.59-0.94) instead of the correct HR of 0.77 (95 % 0.62 − 0.94).